BIO-TECHNE PE ratio TECH

Share price divided by earnings per share over the last twelve months, since 2011.

Today, Oct 23, 2026: 63.1×
10-year median: 61.6×
Against its 10-year history: 53rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 33.3× to 156×
Peer median: 29.3×

BIO-TECHNE's PE ratio is 63.1× as of Oct 23, 2026: a share price of $72.55 against $1.15 of earnings per share over the last twelve months.

That is above its ten-year median of 61.6×, close to the middle of its last ten years.

Over that time it ranged from 33.3× in Nov 2023 to 156× in Sep 2021.

The median for 10 biotech stocks of a similar size is 29.3×.

PE ratio over time

median 61.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	63.1×	62.7×	140×
2025	121×	48.6×	143×
2024	77.6×	43.4×	80.8×
2023	50.8×	33.3×	53.6×
2022	46.5×	42.8×	96.1×
2021	120×	52.0×	156×
2020	50.8×	33.7×	92.3×
2019	91.3×	43.3×	92.9×
2018	42.4×	41.3×	73.0×
2017	66.4×	37.4×	68.3×
2016	39.3×	28.9×	41.0×
2015	31.5×	30.4×	37.7×
2014	32.8×	27.1×	32.8×
2013	30.4×	21.4×	30.4×
2012	22.8×	21.6×	24.3×
2011	22.4×	20.4×	24.0×

Against its peers

Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.

Company	PE ratio
TECHBIO-TECHNE	63.1×
RGENRepligen	242×
KRYSKrystal Biotech	39.0×
HALOHalozyme Therapeutics	37.5×
NBIXNeurocrine Biosciences	20.9×
EXELExelixis	20.3×
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	67.6×
ADMAAdma Biologics	15.3×
Peer median	29.3×

Where BIO-TECHNE ranks

#13of 16Biotech stocks with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on BIO-TECHNE

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.